

CUMULATIVE INDEX 1997

Volume 13

January	UPDATE ON NEUROLOGIC CRITICAL CARE, pages 1-233
April	INTERNATIONAL PERSPECTIVES ON CRITICAL CARE, pages 235-457
July	COMMON ISSUES IN PEDIATRIC AND ADULT CRITICAL CARE, pages 459-707
October	MEDICAL TOXICOLOGY, pages 709-959

Note: Page numbers of article titles are in **boldface** type

Abrin, poisoning by, 850-854
ACE inhibitors, for hypertension in intracerebral hemorrhage, 152-153
N-Acetylcysteine, for anticonvulsant hypersensitivity syndrome, 736-737
Aconitine, poisoning by, 867-870
 structure of, 868
Acquired immunodeficiency syndrome (AIDS), ARF in, **523-552**. See also *Acute respiratory failure (ARF), in AIDS patients*.
Action potentials, cardiac, voltage-gated sodium channels and, 830-833
 phases of, 831-833
Activated charcoal, multiple-dose, in gastrointestinal decontamination following poisoning, 722-723
 versus gastric emptying, in gastrointestinal decontamination following poisoning, 715-717
Acute renal failure, **575-590**
 causes, 576-581
 drug-related, 580-581
 glomerular, 579-580
 hypoxic-ischemic, 576-579
 renal hypoperfusion, 576-579
 vascular, 579-580
 clinical features, 581-583
 defined, 575-576
 dialysis modalities for, 584-585
 in adults, causes, 578-579
 in children, causes, 578
 in newborns and infants, causes, 577-578
 management, conservative, 583-584
 Acute respiratory distress syndrome (ARDS), **503-521**
 clinical features, 506-508
 defined, 504-508
 management, 508-511
 airway pressure release ventilation, 515
 ECCO₂-R, 514-515
 ECMO, 514-515
 high-frequency ventilation, 513-514
 inverse ratio ventilation, 512-513
 IPPV, 510-511
 IVOX, 515
 liquid ventilation, 516-517
 nitric oxide, 515-516
 PEEP, 511-513
 permissive hypercapnia, 512
 pharmacologic agents, 517-518
 surfactants, 515
 pathophysiology, 505-506
 sepsis and, 507-508
 Acute respiratory failure (ARF), in AIDS patients, **523-552**
 causes, 523-526
 diagnostic approach to, 527-531
 pathophysiology, 527
 pneumothoraces complicating, 537-538
 prognostic factors, 538-543
 respiratory isolation issues related to, 526-527
 survival rates, 538-543
 treatment, 531-538

Acute respiratory failure (ARF) (Continued)

- CAPA, 534-536
- clindamycin, 534
- corticosteroids, 532-533
- eflornithine, 534
- mechanical ventilation, 536-537
- pentamine isethionate, 532
- primaquine, 534
- TMP-SMZ, 531-532
- trimetrexate, 533-534
- in children with AIDS, 543-545
- in HIV-seropositive patients, 523-552.
- See also *Acute respiratory failure (ARF), in AIDS patients.*

Adrenal insufficiency, following septic shock in adults, 567

in children, 558

β -Adrenergic blockers, for hypertension in intracerebral hemorrhage, 151

α -Adrenergic blockers, for hypertension in intracerebral hemorrhage, 151

Advocacy, in ICU, 698-699

Africa, aid for, 259

Baragwanath Hospital in, admissions decisions of consultant in, 261-262

critical care in, 255-265

equipment for, 259

organization of, 257-258

patient mix in, 260

staffing for, 259

training for, 256-257

- for doctors, 257
- for nurses, 257-258
- for technologists, 257

life in, described, 255

limited resources in, 260-262

cost containment in presence of, 262-263

population of, 255

size of, 255

β_2 -Agonists, for status asthmaticus, 464-465

Airway pressure release ventilation, for ARDS, 515

Alkaloid(s), *Veratrum*, poisoning by, 864-867

Amebiasis, in South American ICUs, 380

Aminobutyric acid (GABA), enhanced activity of, drugs in, 741-742

Analgesia, in crotalid snake envenomation treatment, 908

Anesthesia/anesthetics, critical care and, 442-443

- for status asthmaticus, 471-472

Anthropometry, in nutritional status assessment, 670

Antibiotic(s), convulsions due to, 741-762.

- See also *Convulsions(s), antibiotic-induced.*

Anticholinergic agents, for status asthmaticus, 466

poisoning by, 875-879

Anticholinergic poisoning syndrome, 802-804

Anticoagulant(s), overdose of, 603-606

Anticonvulsant(s), aromatic, formation of arene oxides by, 732

Anticonvulsant hypersensitivity syndrome, 727-739

- adverse effects associated with, 731
- described, 727
- diagnosis, 736
- felbamate in, 734-736
- incidence, 727
- pathophysiology, 730-736
- phenobarbital in, 730
- phenytoin in, 729-730
- signs and symptoms, 728-730
- treatment, 736-737

Antihypertensive agents, for hypertension in intracerebral hemorrhage, 148-153

Antivenin, in crotalid snake envenomation treatment, 909-914

ARDS. See *Acute respiratory distress syndrome (ARDS).*

ARF. See *Acute respiratory failure (ARF).*

Arginine, in nutritional status assessment, 677

Arrhythmia(s), ventricular, sodium channel blocking agent-related, 834 treatment, 843-844

Arteriovenous fistulas, cerebral, detection of, 73

Arthralgia(s), in anticonvulsant hypersensitivity syndrome, 729

Ascariasis, in South American ICUs, 380

Asia, East, critical care in, 287-298

- cost of, 295-296
- research related to, 296
- types of, 289-290

developing countries of, health trends in, 288-289

economic growth in, 287

ICUs in, 290-295

per capita annual income in, 287

population of, 287

Asthma. See also *Status asthmaticus.*

- care of patient with, 459-460
- characteristics of, 459
- clinical assessment, 462-463
- epidemiology, 460
- pathophysiology, 460-461

Atropine, in nerve agent poisoning treatment, 936-937

Australia, critical care in, 299-316

- consultants for, 303-304
- incident monitoring study in, 311-312
- international links in, 313-314
- manpower for, 307-309
- MOPS in, 312-313
- nurses in, 304-305

organization of, 302–305
 pediatric, 305
 quality assurance in, 310–312
 staffing of, 302–305
 training for, 306–307
 FICANZCA program, 307
 RACP program, 306–307
 geography of, 299–300
 health system organization in, 300–301
 history of, 301–302
 population of, 299
 Australian and New Zealand Intensive Care Society (ANZICS), 309–310
 Autonomic dysfunction, in Guillain-Barré syndrome, 8–9
 Autonomic failure, in Guillain-Barré syndrome, 8–9
 Autoregulation, cerebrovascular reactivity and, 140
 described, 133
 metabolic, 164
 pressure, 165
 A-VDO₂ monitoring of, in traumatic brain injury, 172–174

Baragwanath Hospital, in Africa, admission decisions of consultant in, 261–262
 Benzodiazepine(s), for anticonvulsant hypersensitivity syndrome, 737
 Benzylpenicillin, seizures due to, 745–749
 Biochemical markers, in nutritional status assessment, 670–671
 Bite(s), snake, in South American ICUs, 382
 Blood pressure control, in intracerebral hemorrhage, 147–148
 Blood products, in crotalid snake envenomation treatment, 909–914
 Blood-brain barrier, low hydraulic conductivity of, 109–110
 Starling forces and, 109
 Bradyarrhythmia(s), sodium channel blocking agent-related, 835–836
 treatment, 844–845
 Brain, pathophysiology of, 164–171
 physiology of, 164–171
 Brain attack, 201
 Brain death, determination of, transcranial Doppler ultrasonography in, 98–99
 Brain injury, catabolism following, management, nutritional support in, 40
 high-protein enteral feedings following, 41–45
 hypermetabolism following, management, nutritional support in, 40
 metabolic sequelae of, management, nutritional support in, 39–49

traumatic. See *Traumatic brain injury*.
 Brain protection, etomidate and, 190–192
 history of, 186–187
 inhalational agents and, 189–190
 intravenous agents and, 185–199
 ketamine and, 194–195
 metabolic theory, 187–189
 propofol and, 192–194
 receptor theory, 189
 Brain storming, in critical care medicine, 433
 Brain swelling, following head injury, 617–619
 Bronchoscopy, for status asthmaticus, 468
 Burn(s), nutrition and, 681
 Burnout, in ICU, 697–698
 BZD receptor binding, in antibiotic-induced convulsions, 744–745

Calcium channel blockers, for hypertension in intracerebral hemorrhage, 151–152
 Calorie requirements, of critically ill neurologic patients, 40–41
 Calorimetry, indirect, in nutritional status assessment, 671–672
 Canada, critical care in, 347–362
 costs of, 355–356
 education for, 356–358
 future challenges for, 359–361
 historic milestones in, 348–350
 research related to, 358–359
 services related to, 352–355
 U.S. critical care and, comparison between, 350–359
 Carbamazepine, hypersensitivity associated with, 730
 structure of, 735
 Carbapenem(s), seizures due to, 751–752
 Carbohydrates, in nutritional status assessment, 674–675
 versus fat, in critically ill neurologic patients, 44–45
 Carbon dioxide reactivity, 169–171
 Cardiac action potentials, voltage-gated sodium channels and, 830–833
 Cardiac glycosides, poisoning by, 859–862
 Cardiovascular system, nerve agents effects on, 930–931
 nutritional effects on, 679–680
 septic shock in children effects on, 558–560
 Cardiovascular therapy, following septic shock in adults, 566–567
 Cardiovascular toxicity, 897
 Catabolism, following neurologic injuries, 40
 Catheter(s), jugular bulb. See *Jugular bulb catheter*.

Cefazolin, seizures due to, 749-750
 Central anticholinergic syndrome, 876
 Central nervous system (CNS), nerve agents effects on, 930
 Cephalosporin(s), seizures due to, 749-751
 Cephalothin, seizures due to, 749
 Cerebral blood flow, and oxygen metabolism, relationship between, 165-167
 following traumatic brain injury, 171-172
 head injury effects on, 614-617
 Cerebral hyperemia, mannitol and, 120-121
 Cerebral ischemia, acute, transcranial Doppler ultrasonography in, uses and considerations, 99-100
 described, 133-134
 pathophysiology, 186
 Cerebral metabolism, following traumatic brain injury, 172
 Cerebral oxygen delivery, and consumption, 51-60
 described, 51-52
 Cerebral vasospasm, detection of, transcranial Doppler ultrasonography in, 88-91
 following subarachnoid hemorrhage, development of, 87-88
 in head-injured patients, diagnosis, 72-73
 monitoring of, transcranial Doppler ultrasonography in, 91-92
 Cerebral venous circulation, anatomy of, 61-62
 Cerebroocclusive vascular disease. See *Stroke*.
 Cerebrovascular reactivity, and autoregulation, 140
 Cerebrovascular system, physiology of, 133-139
 Chagas' disease, in South American ICUs, 383
 Charcoal, activated, multiple-dose, in gastrointestinal decontamination following poisoning, 722-723
 versus gastric emptying, in gastrointestinal decontamination following poisoning, 715-717
 Chemical debulking, in osmotherapy, 118
 Chemical warfare, 923-942. See also *Nerve agents, poisoning by*.
 Chest pain, cocaine use and, 809-828
 differential diagnosis, 815-816
 disposition of patients with, 822-824
 evaluation, 816-818
 pathogenesis, 813-815
 treatment, 818-822
 Children, acute renal failure in, causes, 578
 ICUs for, in Australia, 305
 in India, 331-346. See also *India, critical care in, neonatal and pediatric*.
 sepsis in, 553-563
 submersion injuries in. See *Submersion injuries, in children*.
 with AIDS, ARF in, 543-545
 Cictuxin, poisoning by, 854-858
 structure of, 857
 Cilastatin, seizures due to, 751-752
 Circulation, cerebral venous, anatomy of, 61-62
 Cisternal irrigation, prolonged, for subarachnoid hemorrhage, 214-215
 Cl^- ionophore binding, in antibiotic-induced convulsions, 744
 Clindamycin, for ARF in AIDS patients, 534
 Clonazepam, for status epilepticus, 27
 CNS. See *Central nervous system (CNS)*.
 Coagulopathy(ies), acquired, 591-609
 consumptive, 592-602
 DIC, 592-597
 crotalid snake envenomation and, 895-896
 iatrogenic, 602-606
 Cocaine use, chest pain following, 809-828.
 See also *Chest pain, cocaine use and*.
 pharmacology associated with, 810-813
 Codeine, for pain in Guillain-Barré syndrome, 10
 Communications, international organizations and, 441-452
 Internet connections in, 445-451
 links in, 445
 original organizations, 443
 regional organizations, 445
 Consensus, defined, 417
 in critical care medicine, 417-439
 Consensus conferences, in critical care medicine, 417-439
 purposes of, 419
 Consent, informed, ethical issues related to, 413
 Continuous positive airway pressure (CPAP), for ARF in AIDS patients, 534-536
 Convulsion(s), antibiotic-induced, 741-762
 agents in, 745-757
 carbapenems in, 751-752
 cephalosporins in, 749-751
 fluoroquinolones in, 752-754
 isoniazid in, 754-757
 mechanisms of, 744-745
 BZD receptor binding, 744-745
 Cl^- ionophore binding, 744
 direct GABA antagonism, 744
 indirect GABA antagonism, 744-745
 inhibition of GABA synthesis, 745
 metronidazole in, 757
 penicillins in, 745-749

risk factors for, 758
 GABA_A receptor complex in, 742-744
 Corticosteroids(s), for anticonvulsant hypersensitivity syndrome, 737
 Corticosteroid(s), for ARF in AIDS patients, 532-533
 for status asthmaticus, 465
 in crotalid snake envenomation treatment, 908
 Cost containment, in Africa, in presence of limited resources, 262-263
 CPAP. See *Continuous positive airway pressure (CPAP)*.
 Critical care. See also *Intensive care; Intensive care units (ICUs)*.
 and anesthesia, 442-443
 consensus conferences in, 417-439
 alternative methods, 433-436
 archetypes of, 420-422
 ad-hoc process, 421-422
 French national process, 421
 NIH process, 420-421
 brain storming, 433
 decision mapping, 434-435
 Delphi method, 434
 integrative group process, 434-435
 literature evaluation, 430-431
 methods of, 422-430
 foundations of, 436-438
 nominal group technique, 433
 panel meeting activities, 428-430
 panel recommendations, 430
 panelist selection, 431
 performance evaluation, 432-433
 preconference activities, 422-428
 RAND appropriateness rating method, 435-436
 rationale for recommendations, 431
 state-of-the-art process, 436
 structuring of recommendations, 431-432
 defined, 236
 ethics in, international perspectives on, 409-415
 international perspectives on. See also *Ethical issues, in critical care, international perspectives on*.
 history of, 235-236
 in Africa, 255-265. See also *Africa, critical care in*.
 in Australia, 269-316. See also *Australia, critical care in*.
 in Canada, 347-362. See also *Canada, critical care in*.
 in East Asia, 287-298. See also *Asia, East, critical care in*.
 in Europe, 245-254. See also *Europe, critical care in*.
 in India, 317-329. See also *India, critical care in*.
 in Japan, 267-277. See also *Japan, intensive care wards in*.
 in Korea, 277-285. See also *Korea, intensive care wards in*.
 in New Zealand, 299-316. See also *New Zealand, critical care in*.
 in South America, 377-387. See also *South America, critical care in*.
 in United States, 363-376. See also *United States, critical care in*.
 neonatal, in India, evolution of, 331-346.
 See also *India, critical care in, neonatal and pediatric*.
 outcome and resource consumption in, international comparison between, 389-407. See also *Health care, international comparisons of*.
 pediatric, in India, evolution of, 331-346.
 See also *India, critical care in, neonatal and pediatric*.
 worldwide, establishment of, 442-445
 Cromomes, for status asthmaticus, 467
 Crotalid snake envenomation, 889-921
 cardiovascular toxicity associated with, 897
 clinical presentation, 898-902
 coagulopathy associated with, 895-896
 determination of, 905-906
 epidemiology, 890-891
 hematologic disorders associated with, 900-901
 neuromuscular toxicity associated with, 901
 neurotoxicity associated with, 897
 pathophysiology, 891-897
 thrombocytopenia associated with, 896-897
 tissue damage associated with, 892-895, 898-900
 treatment, 902-915
 analgesia in, 908
 blood products in, 909-914
 corticosteroids in, 908
 cryotherapy in, 903
 electric shock therapy in, 905
 excisional therapy in, 915
 fasciotomy in, 914-915
 fluid replacement in, 906
 heat application in, 903
 immobilization in, 902
 incision and suction in, 904
 inhospital, 905-914
 prehospital, 902-905
 pressure immobilization in, 903
 snake venom extractors in, 904
 surgical, 914-915
 tourniquets in, 903-904
 wound care in, 906-908
 Cryotherapy, in crotalid snake envenomation treatment, 903

Decision mapping (DM), in critical care medicine, 434–435

Decontamination, gastrointestinal, following poisoning, 709–725. See also *Gastrointestinal decontamination, following poisoning*.
in nerve agent poisoning treatment, 934–935

Dehydration, osmotherapy and, 121–122

Delphi method, in critical care medicine, 434

Dengue hemorrhagic fever, in South American ICUs, 382

Dialysis, for acute renal failure, 584–585

Diazepam, for status epilepticus, 26

Diazoxide, for hypertension in intracerebral hemorrhage, 150

DIC. See *Disseminated intravascular coagulation (DIC)*.

Digitoxin, structure of, 860

Dilantin sensitivity, 729–730

Disaster medicine, intensive care unit and, 241

Disseminated intravascular coagulation (DIC), 592–597
causes, 593
clinical presentation, 594–595
following septic shock in children, 561–562
management, 595–597
pathophysiology, 593–594

Diving reflex, 487–488

DL- α -fluoromethyl-ornithine, for ARF in AIDS patients, 534

Drowning, defined, 477
in males versus females, 478–479
near, defined, 477
prevalence, 478
secondary, defined, 477–478
wet versus dry, 485–486

Drowning safety enactment, 484–485

Drug(s), acute renal failure due to, 580–581
hyperthermia due to, 785–808. See also *Hyperthermia, drug-induced*.
serotonergic potential of, 771

Drug overdose, 647–667

Dural sinus venous thrombosis, 219–221

East Asia, critical care in, 287–298. See also *Asia, East, critical care in*.

Eastern Europe, critical care in, 250–251

ECCO₂-R, for ARDS, 514–515

ECMO. See *Extracorporeal membrane oxygenation (ECMO)*.

Edema, and hypertension, 144–145
intracerebral hemorrhage and, 143–145

Education, for ICUs in Korea, 281–282
in submersion injury prevention in children, 481–482

Eflornithine, for ARF in AIDS patients, 534

Electric shock therapy, in crotalid snake envenomation treatment, 905

Electroencephalography (EEG), in status epilepticus, 22–24

Electrolyte balance, following septic shock in children, 562

Electrolyte disturbances, osmotherapy and, 121–122

Emergency medical services, in Japan, 273

Emergency medicine, intensive care unit and, 240

Emesis, induced, versus gastric lavage, in gastrointestinal decontamination following poisoning, 709–715

Encephalopathy, hypertensive, 136–137

Enteral nutrition, of critically ill neurologic patients, 41–45
versus parenteral nutrition, of critically ill neurologic patients, 47–48

Enteritis, in South American ICUs, 381

Epidemiology, and preventative medicine, 239–240

Ethic(s), in ICU, 691–701

Ethical issues, in ICUs, described, 409
in India, 324–325
in Western Europe, 249–250

informed consent, 413
international perspectives on, 409–415
principles of, 410
triage and, 410–411
withholding and withdrawing treatments, 412–413

in neonatal ICU in India, 344
of intensivists, 240

Etomidate, and neuroprotection, 190–192
for status epilepticus, 30

Europe, critical care in, 245–254
current status of, 246–251
future aims of, 251, 253
historical background, 245–246
societies of, 251, 252

Eastern, critical care in, 250–251

Western, critical care in, 246–250
bed occupancy of, 247
ethical issues related to, 249–250
ICUs in, number of, 246
nosocomial infection in, 250
patient demography in, 248–249
severity of illness scores and protocols in, 249

staffing of, 247–248
unit size of, 247
unit structure of, 247

Excisional therapy, in crotalid snake envenomation treatment, 915

Extracorporeal membrane oxygenation (ECMO), for ARDS, 514–515
for status asthmaticus, 468

Extracorporeal therapies, following septic shock in children, 562

Eye(s), nerve agents effects on, 931

Fasciotomy, in crotalid snake envenomation treatment, 914-915

Fat, versus carbohydrates, in critically ill neurologic patients, 44-45

FCE22101, seizures due to, 751-752

Federacion Panamericana y Iberica de Medicina Critica y Terapia Intensiva (FEPIIMCTI), 377-379

Felbamate, anticoagulant hypersensitivity syndrome due to, 734-736

for anticonvulsant hypersensitivity syndrome, 737

structure of, 735

Fever, in anticonvulsant hypersensitivity syndrome, 728

Fibrin(ogen)olysis, primary, 598-600

FICANZCA program, 307

Fistula(s), arteriovenous, cerebral, detection of, 73

Fluid replacement, in crotalid snake envenomation treatment, 906

Fluoroquinolone(s), seizures due to, 752-754

Fosphenytoin, for status epilepticus, 27-28

Furosemide, for status asthmaticus, 467

GABA. See *Aminobutyric acid (GABA)*.

GABA_A receptor complex, 742-744

Gabapentin, for anticonvulsant hypersensitivity syndrome, 737

for pain in Guillain-Barré syndrome, 11

Ganglionic blockers, for hypertension in intracerebral hemorrhage, 150-151

Gastric emptying, in gastrointestinal decontamination following poisoning, effect on clinical outcome, 717-722

versus activated charcoal, in gastrointestinal decontamination following poisoning, 715-717

Gastric lavage, versus induced emesis, in gastrointestinal decontamination following poisoning, 709-715

Gastrointestinal decontamination, comparison studies of, 711-713

following poisoning, 709-725

gastric emptying in, effect on clinical outcome, 717-722

versus activated charcoal, 715-717

induced emesis versus gastric lavage in, 709-715

multiple-dose activated charcoal in, 722-723

whole bowel irrigation in, 722

outcome studies of, 718-719

Gastrointestinal system, nerve agents effects on, 932

Genitourinary system, nerve agents effects on, 932

Glutamine, in nutritional status assessment, 675

Glycoside(s), cardiac, poisoning by, 859-862

saponin, poisoning by, 879-883

Grayanotoxin(s), poisoning by, 862-864

Grayanotoxin I, structure of, 864

Guillain-Barré syndrome, 1-15

acute neuromuscular weakness due to, 1

autonomic dysfunction in, 8-9

autonomic failure in, 8-9

clinical presentation, 2-3

described, 1

diagnosis, 3-4

geographic distribution of, 1

immunoglobulin for, 12

incidence, 1

management, ICU, 4, 5, 11

mechanical ventilation in, criteria for, 6

mortality rates, 1-2

nutrition in, 9-10

pain control in, 10-11

plasma exchange for, 11-12

respiratory failure in, 4-8

suxamethonium in, 9

Harris-Benedict equation, 673

Head injuries, 611-628

brain swelling following, 617-619

cerebral blood flow affected by, 614-617

intensive care following, 622-623

motor vehicle-related accidents and, 611

neurologic assessment, 612-613

outcome following, 623-624

resuscitation following, 620-622

secondary injury resulting from, 613-614

seizures following, 619-620

types, 612

Head trauma, cerebral vasospasm due to, diagnosis, 72-73

jugular venous oxygen saturation following, optimal values for, 69-70

transcranial Doppler ultrasonography in, 93-94

uses, 97-98

transcranial Doppler ultrasonography waveforms in, 94-97

Health and Welfare Ministry, of Japan, approval of intensive care wards by, 269

Health care, international comparisons of, 387-407

at-risk population in, 390-392

cross-sectional versus longitudinal study design in, 396

Health care (Continued)

- ICU population in, 392-394
- intrasytem heterogeneity in, 403
- morbidity rates, 399-401
- mortality rates, 397-399
- outcome of, 396-403
- resource consumption, 401-403
- risk adjustment models in, 394-395

Heat, in crotalid snake envenomation treatment, 903

Heliox, for status asthmaticus, 467

Hematologic abnormalities, in anticonvulsant hypersensitivity syndrome, 729

Hematologic disorders, crotalid snake envenomation and, 900-901

Hemolytic-uremic syndrome (HUS), 597-598

Hemorrhage, intracerebral, thrombolytic therapy for. See *Intracerebral hemorrhage*.

- intracranial, transcranial Doppler ultrasonography in, uses, 100
- intraventricular, thrombolytic therapy for, 217-219
- subarachnoid. See *Subarachnoid hemorrhage*.

Heparin, anticoagulant effects of, 605-606

High-frequency ventilation, for ARDS, 513-514

Hookworm disease, in South American ICUs, 380

Hydralazine, for hypertension in intracerebral hemorrhage, 150

Hyoscyamine, structure of, 876

Hypercapnia, permissive, for ARDS, 512 for status asthmaticus, 470-471

Hyperemia, cerebral, mannitol and, 120-121

Hypermetabolism, following neurologic injuries, 40

Hypersmolar state, and osmotic compensation, osmotherapy and, 122-123

Hypersensitivity, to carbamazepine, 730 to phenobarbital, 730 to phenytoin, 729-730

Hypertension, and intracerebral hemorrhage extension, 142-143 and intracerebral hemorrhage outcome, relationship between, 146-147 described, 134-135 edema and, 144-145 in acute intracerebral hemorrhage, 131-161. See also *Intracerebral hemorrhage, hypertension in* intracranial, treatment, 71-73

Hypertensive encephalopathy, 136-137

Hyperthermia, consequences of, 787 drug-induced, 785-808

anticholinergic poisoning syndrome, 802-804

general mechanisms of, 786-787

malignant hyperthermia, 789-793

neuroleptic malignant syndrome, 793-798

sympathomimetic poisoning syndrome, 798-802

syndromes of, 789-804

general principles of, 785-789

malignant, drug-induced, 789-793

thermal homeostasis in, 785-786

treatment, 788-789

Hypertonic saline, for poisoning by sodium channel blocking agents, 845

Hypertonic sodium bicarbonate, sodium channel blocking agents and, 839-841

Hyperventilation, and ischemia, following traumatic brain injury, 175-177

for intracranial hypertension, 71-72

for traumatic brain injury, as acute temporizing measure, 179-180

cerebral ischemia due to, 163-184

chronic prophylactic, 177-179

institution of, 180

intermittent, for transient rises in ICP, 179

recommendations, 179-181

weaning, 180-181

prophylactic, chronic, following traumatic brain injury, 177-179

Hypotension, sodium channel blocking agent-related, treatment, 842-843

ICP. See *Intracranial pressure*.

ICUs. See *Intensive care units (ICUs)*.

Imipenem, seizures due to, 751-752

Immobilization, in crotalid snake envenomation treatment, 902

Immune system enhancers, following septic shock in children, 563

Immunoglobulin(s), for Guillain-Barré syndrome, 12

Immunonutrition, 677-678

India, critical care in, 317-329

- contributions by U.S. organizations to, 328
- current status of, 318-320
- ethical issues related to, 324-325
- future of, 325-326
- history of, 318-320
- neonatal and pediatric, cost of, 343
- current status of, 336-342
- ethical issues in, 344
- evaluation of, 333
- evolution of, 331-346
- existing facilities, 332-333
- IAP program in, 342-343

neonatal perinatal database in, 343-344

PALS program in, 342-343

successful collaboration in, factors contributing to, 344

opportunities for global collaboration in, 326-328

research in, 323-324

spectrum of disease in, 320-323

technology in, 323

infant mortality rate in, 331

National Neonatology Forum of, role in catalyzing neonatal intensive care, 333-334

Neonatal Resuscitation Program of, 336

population of, 331

Indirect calorimetry, in nutritional status assessment, 670-671

Indo-U.S. Faculty Exchange Program, 334-336

Infants, acute renal failure in, causes, 577-578

Infection. See also specific types.

- control of, in ICUs in Japan, 276-277
- nosocomial, in ICUs in Western Europe, 250

Informed consent, ethical issues related to, 413

Inhalational agents, and neuroprotection, 189-190

Inhalational anesthesia, for status asthmaticus, 471-472

Integrative group process (IGP), in critical care medicine, 434-435

Intensive care. See also *Critical care*; *Intensive care units (ICUs)*.

- defined, 236
- evolution of, 235-236
- future of, 242
- interaction with other specialties, 239
- international role of, 241-242
- value of, 237-239

Intensive care medicine, societies of, in Europe, 251, 252

Intensive care physicians. See *Intensivists*.

Intensive care units (ICUs). See also *Critical care*.

- advocacy in, 698-699
- conflict between physicians and nurses in, 694-696
- consent and collaboration in, 692-694
- disaster medicine and, 241
- emergency department and, 240
- ethics in, 691-701
- Guillain-Barré syndrome in, management, 4, 5, 11
- in children, in Australia, 305
- in New Zealand, 305
- in East Asia, 290-295
- in Eastern Europe, 250-251
- in Europe, 245-254
- in Korea, 277-285. See also *Korea, ICUs in*.
- in Western Europe, 246-250. See also *Europe, Western, critical care in*.
- moral distress and burnout in, 697-699
- neurologic, transcranial Doppler ultrasonography in, 79-104. See also *Ultrasonography, transcranial Doppler, in neuro-critical care unit*.
- nurses in, 241
- training in, certification of units for, in Japan, 269
- undergraduate medicine and, 241

Intensive care wards, in Japan, 269-277. See also *Japan, intensive care wards in*.

current status of, 277

Intensivists, board certification of, in Japan, 268-269

- ethical issues related to, 240
- rescue and, 240
- role of, 238
- transport and, 240
- triage and, 240
- value of, 237-239

International federations, communications and, 444-445

International organizations, communications and, 441-452. See also *Communications, international organizations and*.

Internet connections, 445-451

Intracerebral hemorrhage, acute blood pressure control in, 147-148

- described, 131
- edema with, 143-145
- hypertension in, 131-161
- α-adrenergic blockers for, 151
- β-adrenergic blockers for, 151
- ACE inhibitors for, 152-153
- antihypertensive agents for, 148-153
- calcium channel blockers for, 151-152
- diazoxide for, 150
- ganglionic blockers for, 150-151
- hydralazine for, 150
- nicardipine for, 152
- nimodipine for, 152
- nitroglycerin for, 150
- prevalence, 131-132
- sodium nitroprusside for, 149-150
- trimethaphan for, 150-151
- vasodilators for, 149-150

ischemia in, 139-142

PET in, 141

SPECT in, 140-141

systemic complications, 145

thrombolytic therapy for, 215-217

transcranial Doppler ultrasonography in, uses, 100

Intracerebral hemorrhage enlargement, 142-143

Intracranial hypertension, treatment, 71-73

Intracranial pressure (ICP), and volume dynamics, 137-138

elevation of, mannitol and, 120-121

increased, hemodynamic response to, 138-139

management, mannitol in, 113-118

- CSF dynamics and, 117-118
- diuretic theory of, 117
- general considerations, 113-114
- hemodynamic theory of, 115-117
- osmotic theory of, 114-115

Intraoperative intracisternal irrigation, for subarachnoid hemorrhage, 213-214

Intravenous gamma globulin (IVIg), for Guillain-Barré syndrome, 12

Intraventricular conduction defects, sodium channel blocking agents and, 834

Intraventricular hemorrhage, thrombolytic therapy for, 217-219

Invasive positive pressure ventilation (IPPV), for ARDS, 510-511

Inverse ratio ventilation, for ARDS, 512-513

IPPV. See *Invasive positive pressure ventilation (IPPV)*.

Ischemia, defined, 167-169

- following traumatic brain injury, evidence for, 174
- in intracerebral hemorrhage, 139-142

Isoflurane, for status epilepticus, 29-30

Isoniazid, seizures due to, 754-757

IVOX, for ARDS, 515

Japan, emergency medical services in, 273

- ICUs in, described, 277-279
- intensive care wards in, 267-277
- beds in, number of, 270-271
- board certification of intensive care physicians in, 268-269
- certification of units for intensive care training in, 269
- current status of, 270-277
- facilities in, 275-276
- Health and Welfare Ministry approval of, 269
- history of, 267-268
- infection control in, 276-277
- medical equipment and devices in, 274-275
- number of, 270
- nursing staff in, 273-274
- organization of, 272-273
- paramedical personnel in, 274
- physician specialties in, 272
- staffing of, 271-272

Japanese Society of Intensive Care Medicine (JSICM), described, 268

Jugular bulb catheter. See also *Jugular venous oxygen saturation (Sjvo₂)*, for cerebral hemodynamic monitoring, for cerebral hemodynamic monitoring, 51-77

- insertion of, 64-65
- maintenance of, 65

Jugular venous blood, extracranial

- contamination of, 62-63
- mixing of, 62

Jugular venous desaturation, diagnosis and management, 71

Jugular venous oxygen saturation (Sjvo₂), changes in, with cerebral ischemia, 55-57

- with decreased arterial oxygen content, 52-55
- with increases in cerebral metabolic rate, 57-60

during cardiovascular surgery, optimal values for, 69

following head injury, optimal values for, 69-70

for cerebral hemodynamic monitoring, 51-77

- complications, 67-68
- contraindications, 67
- indications, 65-67
- limitations, 73
- technical aspects of, 61-65

ischemic thresholds for, 68-69

normal values, 68

Ketamine, and neuroprotection, 194-195

Ketorolac, for pain in Guillain-Barré syndrome, 10

Korea, critical care in, 277-285. See also *Korea, ICUs in*.

- ICUs in, academic activity and education for, 281-282
- application for revision of fees for medical treatment in, 284-285
- improvement ideas for, 284
- medical equipment and monitoring systems in, 282-283
- organization of, 279
- staffing of, 279-281

intensive care wards in, 267-277

Leptospirosis, in South American ICUs, 383

Lidocaine, for status epilepticus, 31

Lipid(s), in nutritional status assessment, 673

Liquid ventilation, for ARDS, 516-517

Liver abnormalities, in anticonvulsant hypersensitivity syndrome, 728-729

Liver dysfunction, nutrition and, 680

Lorazepam, for status epilepticus, 26

Lymphadenopathy, in anticonvulsant hypersensitivity syndrome, 728

Magnesium sulfate, for status asthmaticus, 467

Malaria, in South American ICUs, 381–382

Malignant hyperthermia, drug-induced, 789–793

Mannitol, and midline shift, 123–124

ICP elevation due to, 120–121

in ICP management, 113–118

in neurocritical care, uses, 113–119

nonosmotic actions of, 111–112

Mannitol drip, 119

Massive transfusion syndrome, 603

Mechanical ventilation, for ARF in AIDS patients, 536–537

for status asthmaticus, 468–471

complications, 471

indications, 468

modes of, 470

muscle relaxants, 471

permissive hypercapnia, 470–471

tracheal intubation, 468–470

in Guillain-Barré syndrome, criteria for, 6

noninvasive, for status asthmaticus, 468

Metabolic autoregulation, 164

Metabolism, following septic shock in children, 562

Methylprednisolone, for status asthmaticus, 465

Methylxanthines, for status asthmaticus, 465–466

Metronidazole, seizures due to, 757

Mexitilene, for pain in Guillain-Barré syndrome, 11

Midazolam, for status epilepticus, 27

Minerals, in critically ill neurologic patients, 45

MOPS, 312–313

Moral distress, in ICU, 697–698

Morphine, for pain in Guillain-Barré syndrome, 10

Motor vehicle-related accidents, head injuries due to, 611

Mucolytic therapy, for status asthmaticus, 468

Muscle relaxants, to facilitate mechanical ventilation for unstable asthmatic patients, 471

Musculoskeletal system, nerve agents effects on, 931

Myalgia(s), in anticonvulsant hypersensitivity syndrome, 729

Narcotics, for pain in Guillain-Barré syndrome, 10

National Neonatology Forum of India, 333–334

Near drowning, defined, 477

Negative inotropic effect, sodium channel blocking agents and, 835

Neonatal Resuscitation Program, in India, 336

Neonates, critical care for, in India, 331–346. See also *India, critical care in, neonatal and pediatric*.

Nerve agents, chemical properties of, 925

mechanism of action of, 925–928

poisoning by, 923–942

assessment, 935–936

cardiovascular effects of, 930–931

clinical presentation, 928–932

CNS effects of, 930

dermal effects of, 932

gastrointestinal effects of, 932

genitourinary effects of, 932

history of, 923–925

laboratory studies, 932–933

musculoskeletal effects of, 931

ocular effects of, 931

respiratory effects of, 929–930

treatment, 933–938

antidotal, 936–938

atropine in, 936–937

decontamination in, 934–935

disposition in, 938

pralidoxime chloride in, 937–938

Neurointensive care, thrombolytic therapy in, 201–227

transcranial Doppler ultrasonography in, 79–104

Neuroleptic malignant syndrome, drug-induced, 793–798

versus serotonin syndrome, 776, 777

Neuroprotection, intravenous agents and, 185–199. See also *Brain protection*.

Neurotoxicity, 897

crotalid snake envenomation and, 901

New Zealand, critical care in, 299–316

consultants for, 303–304

international links in, 313–314

manpower for, 307–309

nurses in, 304–305

organization of, 302–305

pediatric, 305

quality assurance in, 310–312

staffing of, 302–305

training for, 306–307

FICANZCA program, 307

RACP program, 306–307

health system organization in, 300–301

population of, 300

Newborns, acute renal failure in, causes, 577–578

Nicardipine, for hypertension in intracerebral hemorrhage, 152

Nicotine, poisoning by, 870-875
structure of, 873

NIH health technology assessment, 420-421

Nimodipine, for hypertension in intracerebral hemorrhage, 152

Nitric oxide, for ARDS, 515-516

Nitrogen, in critically ill neurologic patients, 41

Nitroglycerin, for hypertension in intracerebral hemorrhage, 150

Nominal group technique, in critical care medicine, 433

Nonpacemaker cells, 831-833

Nortriptyline, for pain in Guillain-Barré syndrome, 11

Nosocomial infection, in ICUs in Western Europe, 250

Nurse(s), in ICUs, in Australia, 304-305
in Japan, 273-274
role of, 241
training for, in Africa, 256-257

Nutritional management, in Guillain-Barré syndrome, 9-10
of critically ill neurologic patients, 39-49
calorie requirements, 40-41
early feeding, 45-47
fat versus carbohydrate calories, 44-45
high-protein enteral feedings, 41-45
minerals, 45
nitrogen requirements, 41
parenteral versus enteral nutrition, 47-48
vitamins, 45

Nutritional status, 669-690
assessment, 669-672
anthropometry in, 670
arginine in, 677
biochemical markers in, 670-671
glutamine in, 677
indirect calorimetry in, 670-671
multiparameter tools in, 671
omega-3 fatty acids in, 678
RNA in, 677
substrates in, 672-676
burns and, 680
caloric requirements for, 673-674
carbohydrates in, 673-674
cardiovascular disease and, 677-680
following septic shock in children, 562
immunonutrition, 677-678
lipids in, 675
liver dysfunction and, 680
organ system issues in, 678-682
proteins in, 675-676
renal failure and, 681-682
respiratory failure and, 678-679
route-related complications in, 676-678

sepsis and, 680
wound healing and, 682

Oleandrin, structure of, 860

Omega-3 fatty acids, in nutritional status assessment, 678

Osmotherapy, 105-129. See also *Osmotic agents*.
adverse acute hemodynamic effects of, 119-126
and brain pathology, 110-111
chemical debulking in, 118
dehydration due to, 121-122
electrolyte disturbances due to, 121-122
hemorrhagic effects of, 119
historical background of, 106-107
limitations, 119-126
pharmacokinetics, 112-113
pitfalls of, 119-126
rebound phenomenon of, 125-126
renal clearance in, 112-113
Osmotic agents, actions of, 107-112
and tonicity, 108-109
delivery of, 105-129. See also *Osmotherapy*.
 effects of, 107-108
 hemorrhagic effects, 119

Oximetry, in vivo, 60-61

Oxygen, for status asthmaticus, 463-464
Oxygen metabolism, and cerebral blood flow, relationship between, 165-167

Pacemaker cells, 833

Pain, chest. See *Chest pain*.

in Guillain-Barré syndrome, control of, 10-11

Paraldehyde, for status epilepticus, 30-31

Paramedical personnel, in ICUs in Japan, 274

Parenteral nutrition, versus enteral nutrition, in critically ill neurologic patients, 47-48

PEEP. See *Positive end-expiratory pressure (PEEP)*.

Penicillin(s), seizures due to, 745-749

Pentamine isethionate, for ARF in AIDS patients, 532

Pentobarbital, for status epilepticus, 29

Peripheral anticholinergic syndrome, 877

Permissive hypercapnia, for ARDS, 512
 for status asthmaticus, 470-471

PET. See *Positron emission tomography (PET)*.

Pharmacologic agents, for ARDS, 517-518

Phenobarbital, for status epilepticus, 28
 hypersensitivity associated with, 730

structure of, 735

Phenobarbital hypersensitivity, 730

Phenytoin, for status epilepticus, 27–28
rashes associated with, 729–730
structure of, 735

Phytolaccagenen from poke, structure of, 881

Plant poisoning, life-threatening, 849–888
aconitine in, 867–870
anticholinergics in, 875–879
cardiac glycosides in, 859–862
cicutoxin in, 854–858
grayanotoxins in, 862–864
management, 849–850
nicotine in, 870–875
saponin glycosides in, 879–883
toxalbumins in, 850–854
Veratrum alkaloids in, 864–867

Plasma exchange, for Guillain-Barré syndrome, 11–12

Pneumocystis carinii pneumonia, ARF secondary to, 527

Pneumonia, *Pneumocystis carinii*, ARF secondary to, 527

Pneumonitis, in anticonvulsant hypersensitivity syndrome, 729

Pneumothorax, spontaneous, as complication of respiratory failure in AIDS patients, 537–538

Poison(s), in South American ICUs, 382

Poisoning, 647–667
advanced supportive techniques for, 659–662
antidotes for, 655–658
basic supportive care for, 649–653
by sodium channel blocking agents, 829–848. See also *Sodium channel blocking agents, poisoning by*
gastrointestinal decontamination following, 709–725. See also *Gastrointestinal decontamination, following poisoning*.
nerve agent, 923–942. See also *Nerve agents, poisoning by*.
plant, life-threatening, 849–888. See also *Plant poisoning, life-threatening*.
treatment, novel approaches to, 658–659

Positive end-expiratory pressure (PEEP), for ARDS, 511–513

Positron emission tomography (PET), in intracerebral hemorrhage, 141

Pralidoxime chloride, in nerve agent poisoning treatment, 937–938

Pressure autoregulation, 165

Pressure immobilization, in crotalid snake envenomation treatment, 903

Primaquine, for ARF in AIDS patients, 534

Primary fibrin(ogen)olysis, 598–600

Propofol, and neuroprotection, 192–194
for status epilepticus, 30

Protein(s), in nutritional status assessment, 675–676

Protogerine, structure of, 866

Purpura fulminans, following septic shock in children, 561–562

QRS prolongation, sodium channel blocking agent-related, treatment, 842

Quality assurance, in ICUs in Australia and New Zealand, 310–312

RACP program, in Australia, 306–307

RAND appropriateness rating method, in critical care medicine, 435–436

Rash(es), in anticonvulsant hypersensitivity syndrome, 728
phenytoin and, 729–730

Renal clearance, in osmotherapy, 112–113

Renal dysfunction, in anticonvulsant hypersensitivity syndrome, 729

Renal failure, nutrition and, 680–681
septic shock in children effects on, 560–561

Renal hypoperfusion, acute renal failure due to, 576–579

Reperfusion, 186

Rescue, intensivists role in, 240

Respiratory failure, acute. See *Acute respiratory failure (ARF)*.
in Guillain-Barré syndrome, 4–8
nutrition and, 678–679
septic shock in children effects on, 560

Respiratory system, nerve agents effects on, 929–930

Resuscitation, following head injury, 620–622

Rhabdomyolysis, in anticonvulsant hypersensitivity syndrome, 729

Ricin, poisoning by, 850–854

Ricinus communis, poisoning by, 850–854

Ritipenem (FCE22101), seizures due to, 751–752

RNA, in nutritional status assessment, 677

rt-PA, for stroke, 205

Saponin glycosides, poisoning by, 879–883

Schistosomiasis, in South American ICUs, 380–381

Scopolamine, structure of, 876

Secondary drowning, defined, 477–478

Seizure(s), antibiotic-induced, 741–762. See also *Convulsion(s), antibiotic-induced*.
following head injury, 619–620

Seizure disorders, submersion accidents in patients with, 479

Sepsis, and ARDS, 507-508
 following trauma, in South American ICUs, 383
 nutrition and, 680

Septic shock, **553-574**
 in adults, 563-568
 adrenal insufficiency following, 567
 airway and breathing following, 565
 antibiotics following, 567-568
 cardiovascular therapy following, 566-567
 pathogenesis, 564
 predisposing factors, 564-565
 prevention, 565
 recognition of, 565
 resuscitation following, 565-568
 stabilization following, 568
 volume resuscitation following, 565-566

in children, 553-563
 adrenal insufficiency following, 558
 airway and breathing following, 557
 antibiotic therapy following, 558
 cardiovascular failure following, 558-560
 cardiovascular therapy following, 557-558
 DIC following, 561-562
 drug metabolism following, 562
 early recognition of, 556-557
 electrolyte balance following, 562
 extracorporeal therapies following, 562
 factors predisposing to, 555-556
 immune system enhancers following, 563
 metabolism following, 562
 nutritional needs following, 562
 pathogenesis, 553-555
 prevention, 556
 purpura fulminans following, 561-562
 renal failure following, 560-561
 respiratory failure following, 560
 resuscitation following, 557-558
 stabilization following, 558-563
 volume resuscitation following, 557

Serotonergic potential of drugs, 771

Serotonin, anatomy related to, 767
 function of, 765-766
 metabolism of, 767-768
 physiology of, 765-769
 psychopharmacology of, 770-773
 synthesis of, 767-768

Serotonin receptors, 768-769

Serotonin syndrome, **763-783**
 ancillary tests, 775-776
 clinical presentation, 773-775
 described, 763
 diagnosis, 764-765
 differential diagnosis, 776
 history of, 764
 laboratory tests, 775-776
 pathophysiology, 769-770
 treatment, 776, 778-779
 versus neuroleptic malignant syndrome, 776, 777

Shock, septic. See *Septic shock*

Single photon emission computed tomography (SPECT), in intracerebral hemorrhage, 140-141

Sinus venous thrombosis, dural, 219-221

Skin, nerve agents effects on, 932

Snake bites, in South American ICUs, 382
 prevalence, 889

Snake venom extractors, in crotalid snake envenomation treatment, 904

Society of Critical Care Medicine (SCCM), establishment of, 367, 369-370
 role of, 370-371

Sodium channel(s), voltage-gated, and cardiac action potentials, 830-833

Sodium channel blocking agents, bradycardia due to, 835-836

hypertonic sodium bicarbonate and, 839-841

intraventricular conduction defects due to, 834

myocardial toxicity due to, 833-838

negative inotropic effect due to, 835
 poisoning by, **829-848**
 bradycardia due to, treatment, 844-845
 features, 838
 hypertonic saline for, 845
 hypotension due to, treatment, 842-843

QRS prolongation due to, treatment, 842

supraventricular tachyarrhythmias due to, treatment, 845

treatment, 841-845

ventricular arrhythmias due to, treatment, 843-844

tachyarrhythmia effects on, 836-838

ventricular arrhythmias due to, 834

Sodium nitroprusside, for hypertension in intracerebral hemorrhage, 149-150

Solumedrol, for pain in Guillain-Barré syndrome, 10

South America, critical care in, **377-387**
 amebiasis in, 380
 ascariasis in, 380
 Chagas' disease in, 383
 dengue hemorrhagic fever in, 382
 enteritis in, 381

Federacion Panamericana y Iberica de Medicina Critica y Terapia Intensiva in, 377-379

future of, 386-387

government's role in, 385

hookworm disease in, 380
 leptospirosis in, 383
 malaria in, 381-382
 organization and funding of health care in, 383-384
 poisons in, 382
 population in, 380-383
 proposed solutions in, 386
 schistosomiasis in, 380-381
 sepsis following trauma in, 383
 snake bites in, 382
 survey on, 379
 technology in, 384-385
 tetanus in, 382
 tuberculosis in, 381
 within health care, 385-386

Specialty, characteristics of, 236-237
 SPECT. See *Single photon emission computed tomography (SPECT)*.
 Starling forces, blood-brain barrier and, 109
 State-of-the-Art method, in critical care medicine, 436
 Status asthmaticus, 459-476. See also *Asthma*.
 management, 463-472
 β_2 -agonists, 464-465
 anticholinergic agents, 466
 bronchoscopy, 468
 corticosteroids, 465
 cromomes, 467
 ECMO, 468
 furosemide, 467
 future approaches to, 472
 heliox, 467
 inhalational anesthesia, 471-472
 magnesium sulfate, 467
 mechanical ventilatory support, 468-471
 methylxanthines, 465-466
 oxygen, 463-464

Status epilepticus, 17-38, 629-646
 classification of, 18, 19, 631-633
 clinical manifestations, 636-638
 defined, 17
 diagnostic approach to, 638-639
 EEG changes in, 22-24
 epidemiology, 18-19, 629-631
 historical background of, 17-18
 management, 639-644
 pathogenesis, 633-636
 pathophysiology, 19-22, 633-636
 prognosis, 33-35
 radiographic scan changes in, 24
 treatment, clonazepam, 27
 complications, 32-33
 diazepam, 26
 etomidate, 30
 fosphenytoin, 27-28
 future of, 35

general considerations, 24-25
 isoflurane, 29-30
 lidocaine, 31
 lorazepam, 26
 midazolam, 27
 paraldehyde, 30-31
 pentobarbital, 29
 pharmacotherapy, 25-31
 phenobarbital, 28
 phenytoin, 27-28
 propofol, 30
 protocol for, 31-32
 thiopental, 28-29

Streptokinase, for stroke, 206
 Stroke, described, 201-202
 incidence, 201
 mortality rates, 201
 rt-Pa for, 205
 streptokinase for, 206
 thrombolytic therapy for, 202-211

Subarachnoid hemorrhage, cerebral
 vasospasm following, development of, 87-88
 inoperable, high-grade, 215
 management, transcranial Doppler ultrasonography in, 92-93
 thrombolytic therapy for, 211-215

Submersion injuries, 477-502
 epidemiology, 478-481
 future directions related to, 497-498
 in bathtubs, 481
 in buckets, 481
 in children, prevalence, 478-479
 prevention, 481-485
 drowning safety enactment in, 484-485
 education in, 481-482
 personal safety enforcement in, 485
 public health engineering in, 483
 in hot tubs, 481
 in natural bodies of water, 480-481
 in spas, 481
 in swimming pools, 479
 management, 491-497
 at scene, 491-493
 cardiovascular, 495-496
 emergency department care, 493-494
 ICU, 494
 neurologic resuscitation, 496-497
 respiratory, 494-495
 neurologically based problems in, 486-487
 pathophysiology, 485-489
 prognostic predictors following, 489-491
 seizure disorders and, 479

Substrate(s), 672-676
 metabolism of, in nutritional status assessment, 672-673

Supraventricular tachyarrhythmias, sodium channel blocking agent-related, treatment, 845

Surfactant(s), for ARDS, 515

Suxamethonium, in Guillain-Barré syndrome, 9

Sympathomimetic poisoning syndrome, drug-induced, 798-802

Tachyarrhythmia(s), effects on sodium channel blocking agents, 836-838

supraventricular, sodium channel blocking agent-related, treatment, 845

Technologists, training for, in Africa, 257

Tetanus, in South American ICUs, 382

Theophylline, for status asthmaticus, 465-466

Thermal homeostasis, hyperthermia and, 785-786

Thiopental, for status epilepticus, 28-29

Thrombocytopenia, crotalid snake envenomation and, 896-897

Thrombolysis, intraarterial, for stroke, 209-211

intravenous, for stroke, 202-209

Thrombolytic therapy, for intracerebral hemorrhage, 215-217

for intraventricular hemorrhage, 217-219

for stroke, 202-211

for subarachnoid hemorrhage, 211-215

in neurointensive care, 201-227

recommendations, 221

stroke-related applications of, 221

Thrombosis, dural sinus venous, 219-221

Thrombotic thrombocytopenic purpura (TTP), 597-598

Thyroiditis, in anticonvulsant hypersensitivity syndrome, 729

TMP-SMZ. See *Trimethoprim-sulfamethoxazole (TMP-SMZ)*.

Toddlers, submersion injuries in, 478-479

Tonicity, and osmotic reflection, 108-109

Tourniquets, in crotalid snake envenomation treatment, 903-904

Toxalbumin(s), poisoning by, 850-854

Toxin removal, acceleration of, 653-655

Tracheal intubation, for status asthmaticus, 468-470

Transport, intensivists role in, 240

Trauma, head. See *Head trauma*.

sepsis following, in South American ICUs, 383

Traumatic brain injury, cerebral blood flow following, 171-172

cerebral metabolism following, 172

costs of care following, 163

head injury and, 613-614

incidence, 163

ischemia following, evidence for, 174

hyperventilation and, 175-177

monitoring A-VDO₂ in, 172-174

prevalence, 163

problems related to, 163

studies in, 171-174

treatment, cerebral ischemia due to, 163-184

Triage, ethical issues related to, 410-411

intensivists role in, 240

Trimethaphan, for hypertension in intracerebral hemorrhage, 150-151

Trimethoprim-sulfamethoxazole (TMP-SMZ), for ARF in AIDS patients, 531-532

Trimetrexate, for ARF in AIDS patients, 533-534

Tuberculosis, in South American ICUs, 381

Ultrasonography, transcranial Doppler, cerebral vasospasm detection by, 88-91

in acute cerebral ischemia, uses and considerations, 99-100

in brain death determination, 98-99

in examination of cerebral vessels, 82-87

in head trauma, 93-94

uses, 97-98

in intracerebral hemorrhage, uses, 100

in neuro-critical care unit, 79-104

future directions in, 93

limitations, 87

in subarachnoid hemorrhage management, 92-93

limitations, in vasospasm monitoring, 91-92

principles of, 80-82

waveforms, in head trauma, 94-97

Undergraduate medicine, intensive care unit and, 241

United States, critical care in, 363-376

accomplishments of, 371-372

Canadian critical care and, comparison between, 350-359

current status of, 365-367

future research for, 372

historical background of, 363-365

impact of changing health care system on, 372-374

Society of Critical Care Medicine in, 367, 369-371

Valproate, for anticonvulsant hypersensitivity syndrome, 737

Valproic acid, for pain in Guillain-Barré syndrome, 11

Vasodilating agents, for hypertension in intracerebral hemorrhage, 149-150

Vasospasm, cerebral. *See Cerebral vasospasm.*

Ventilation, airway pressure release, 515
high-frequency, for ARDS, 513-514
inverse ratio, for ARDS, 512-513
liquid, for ARDS, 516-517
mechanical. *See Mechanical ventilation.*

Ventricular arrhythmias, sodium channel blocking agent-related, 834
treatment, 843-844

Veratrum alkaloids, poisoning by, 864-867

Vigabatrin, for anticonvulsant hypersensitivity syndrome, 737

Vitamin(s), in critically ill neurologic patients, 45

Vitamin K-related disorders, 600-602
causes, 600-601
clinical presentation, 601-602
management, 602

pathophysiology, 600-601

Volume resuscitation, following septic shock in adults, 565-566

Warfarin, anticoagulant effects of, 603-605

Western Europe, critical care in, 246-250.
See also Europe, Western, critical care in.

Whole bowel irrigation, in gastrointestinal decontamination following poisoning, 722

Withdrawal of treatment, ethical issues related to, 412-413

Withholding of treatment, ethical issues related to, 412-413

Wound healing, nutrition and, 682